Regeneron Pharmaceuticals logged a 1.07% change during today's aftermarket session, and is now trading at a price of $760.42 per share. On average, analysts give it a target price of $840.26.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. If you are thinking buying Regeneron Pharmaceuticals should be aware of the facts below:
-
Regeneron Pharmaceuticals has moved 14.61% over the last year.
-
Based on its trailing earning per share of 38.32, Regeneron Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of 19.84
-
REGN has a forward P/E ratio of 17.79.
-
The company has a price to earnings growth (PEG) ratio of 9.01 — a number between 0 and 1 signifying that Regeneron Pharmaceuticals is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 3.81
-
The large-cap company is based in the United States. Regeneron Pharmaceuticals currently returns an annual dividend yield of 0.0%.
-
Here's an overview of the company's last 5 years of cash flows:
| Date Reported | Cash Flow from Operations (k) | Capital Expenditures (k) | Free Cash Flow (k) | YoY Growth |
|---|---|---|---|---|
| 2022-12-31 | $5,014,900 | $590,100 | $4,424,800 | -32.23% |
| 2021-12-31 | $7,081,300 | $551,900 | $6,529,400 | 225.9% |
| 2020-12-31 | $2,618,100 | $614,600 | $2,003,500 | 0.15% |
| 2019-12-31 | $2,430,000 | $429,600 | $2,000,400 | 10.4% |
| 2018-12-31 | $2,195,100 | $383,100 | $1,812,000 | n/a |
